Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Blood Adv. 2023 Jul 25;7(14):3677-3679. doi: 10.1182/bloodadvances.2023009781.
No abstract available

MeSH terms

  • Activin Receptors, Type II
  • Anemia* / drug therapy
  • Anemia* / etiology
  • Humans
  • Immunoglobulin Fc Fragments / therapeutic use
  • Myelodysplastic Syndromes* / complications
  • Myelodysplastic Syndromes* / drug therapy

Substances

  • luspatercept
  • Immunoglobulin Fc Fragments
  • Activin Receptors, Type II